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Background:  Controversy  exists  whether  heart  transplantation  (HTx)  is an  appropriate  treatment  option
for patients  with  cardiac  sarcoidosis  due  to  its  potential  recurrence  and  multi-organ  involvement.  Recent
data  from  the  United  Network  for  Organ  Sharing  dataset  suggest  that the  clinical  outcome  of  cardiac
sarcoidosis  patients  is  equivalent  or even  better  than  that  of  the  general  HTx  population.
Methods:  We  retrospectively  reviewed  the  clinical  course  of  14  patients  with  cardiac  sarcoidosis  among
a  total of  825  patients  who  underwent  HTx  at Columbia  University  Medical  Center  between  1997 and
2010.  Post-transplant  survival  of  patients  with  sarcoidosis  was  compared  with  that  of  non-sarcoidosis
patients.
Results:  More  than  half of  cardiac  sarcoidosis  patients  were  initially  diagnosed  after  HTx  by  tissue  analysis
of  the  explanted  heart.  While  only  2/14  cases  showed  recurrence  of  cardiac  sarcoidosis,  the  clinical  out-
come of sarcoid  patients  showed  a  trend  toward  higher  mortality  than  that  of  non-sarcoidosis  patients
following  HTx  (1- and  5-year  survival,  78.5 versus  87.2%,  52.4 versus  76.2%,  respectively,  p  = 0.09).
Conclusions:  Although  this  is  a single-center,  retrospective  analysis  of a small  number of  cardiac  sarcoido-
sis patients  who  underwent  HTx, a concerning  trend  toward  a higher  mortality  of  patients  with  cardiac
sarcoidosis  was noted.  A careful  candidate  selection  in  patients  with  known  cardiac  sarcoidosis  should
be discussed.
2  Jap©  201
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Sarcoidosis is a multi-organ disease which can affect the heart
eading to a progressive inﬁltrative cardiomyopathy. Heart trans-
lantation (HTx) is an effective therapy for patients with end-stage
eart failure (HF) and the outcome of patients with cardiac sar-
oidosis has been reported to be identical to or even better than that
n non-sarcoidosis patients [1–3]. However, multi-organ involve-
ent of this disease and recurrence of sarcoidosis in a transplanted
eart have been reported previously [4,5]. Therefore, debate exists
egarding the appropriateness of HTx for patients with cardiac
arcoidosis due to the possibility of disease recurrence and involve-
ent of other organs with potential development of multi-organ
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edicine, Division of Cardiology, 622 West 168th Street, PH 10, Room 203, New
ork, NY 10032, USA. Tel.: +1 212 305 6916; fax: +1 212 342 5355.
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914-5087/$ – see front matter © 2012 Japanese College of Cardiology. Published by Else
ttp://dx.doi.org/10.1016/j.jjcc.2012.07.013anese  College  of  Cardiology.  Published  by  Elsevier  Ltd.  All rights  reserved.
dysfunction. We here review the post-transplant clinical course of
HTx recipients with cardiac sarcoidosis at our institution.
Methods
Patients and study design
Among a total of 825 patients undergoing HTx at Columbia Uni-
versity Medical Center, New York, USA, between March 1997 and
May  2010, 14 patients were diagnosed with cardiac sarcoidosis as a
primary cause of HF either pre-operatively or at the time of trans-
plantation. Clinical course was  reviewed retrospectively by chart
review. Survival after heart transplantation of sarcoidosis patients
was compared with the survival of non-sarcoidosis patients trans-
planted at our institution.Statistical analysis
Data are presented as means ± SD. Normality was evaluated
for each variable on the basis of normal distribution plots and
vier Ltd. All rights reserved.
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Table  1
Baseline characteristics.
Sarcoidosis Non-sarcoidosis p-Value
Recipient age (years) 51 ± 9 53 ± 4 0.4748
Gender, female (%) 50 22.8 0.0002
BMI  (kg/m2) 26.1 ± 1.3 25.7 ± 2.0 0.7240
Hypertension (%) 42.9 38.8 0.8890
Diabetes mellitus (%) 28.6 28.4 0.9243
Pre-Op  LVAD (%) 50.0 31.76 0.1471
Ethnicity (%) 0.0034
African American 50.0 13.9
Caucasian 28.6 62.9
Other 14.3 10.5
Hispanic 7.1 9.8
Asian 0 3.0
UNOS status (%) 0.4037
Status 1A 35.7 45.9
Status 1B 50.0 38.4
Status 2 14.3 15.7
Laboratory values
Hematocrit (%) 37.6 ± 5.3 36.2 ± 6.2 0.4542
BUN  (mg/dL) 23.4 ± 11.3 29.0 ± 15.7 0.1999
Creatinine (mg/dL) 1.23 ± 0.3 1.39 ± 0.8 0.5020
AST  (U/L) 25.9 ± 11.4 34.8 ± 59.9 0.609
ALT  (U/L) 24.5 ± 13.7 35.5 ± 72.3 0.615
Total  bilirubin (mg/dL) 0.8 ± 0.4 1.1 ± 1.0 0.229
Total  protein (g/dL) 7.3 ± 0.7 7.2 ± 0.9 0.552
Albumin (g/dL) 3.6 ± 0.4 3.9 ± 0.6 0.057
Glucose (mg/dL) 101.2 ± 21.0 108.1 ± 44.8 0.6086
HbA1c  (%) 6.0 ± 0.8 6.0 ± 0.4 0.913
Triglycerides (mg/dL) 120.5 ± 67.8 122.7 ± 78.8 0.9266
Cholesterol (mg/dL) 157.4 ± 47.6 150.8 ± 45.7 0.5936
HDL  (mg/dL) 34.0 ± 6.1 38.3 ± 14.1 0.3576
LDL  (mg/dL) 98.7 ± 49.4 87.3 ± 34.6 0.3299
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mata are means ± SD. BMI, body mass index; Pre-Op LVAD, pre-operative left ventri
ST,  aspartate aminotransferase; ALT, alanine aminotransferase; HbA1c, hemoglob
istograms and by the Kolmogorov–Smirnov test. Clinical charac-
eristics and laboratory data were compared between groups using
tudent’s unpaired two-tailed t test or chi-square analysis. Survival
fter HTx was compared between the groups using Kaplan–Meier
nalysis and log-rank statistics. All statistical analyses were per-
ormed using the JMP  7.0 software (SAS Institute, Cary, NC, USA).
esults
Patients with sarcoidosis undergoing cardiac transplantation
id not differ from non-sarcoidosis patients in regard to age, clinical
istory, pre-HTx left ventricular assist device (LVAD) requirement
r United Network for Organ Sharing (UNOS) status at the time of
Tx. The ethnic group of the patients included 7 African-American,
 Caucasian, 1 Hispanic-American, and 1 other race. In patients with
ardiac sarcoidosis, a signiﬁcantly higher percentage of females
nd African-Americans was noted when compared to the non-
arcoidosis group (Table 1).
Six patients (42.9%) were diagnosed with sarcoidosis before
Tx with one patient diagnosed by right ventricular endomyocar-
ial biopsy, one patient diagnosed on myocardial core tissue at
he time of LVAD implantation, and 4 patients diagnosed by pre-
xisting concomitant pulmonary sarcoidosis with end-stage HF. In
hese patients with pulmonary sarcoidosis, due to histologically
onﬁrmed extra-cardiac sarcoidosis accompanied by HF, their HF
tiologies were considered as cardiac sarcoidosis [6].  The remaining
 patients (57.1%) were eventually diagnosed with cardiac sar-
oidosis at the time of HTx by the histological evaluation of the
xplanted hearts. Seven patients (50%) had concomitant pulmonary
arcoidosis, including one patient who developed abnormal ﬁnd-
ngs on chest X-ray and pulmonary sarcoidosis was diagnosed after
ransplant. Among the 6 patients who received a diagnosis of pul-
onary sarcoidosis before HTx, 3 patients (3/6, 50%) died at 9 days,assist device; UNOS, United Network for Organ Sharing; BUN, blood urea nitrogen;
; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
2.6 months, and 30.8 months post-transplant (Table 2). One  of these
patients experienced recurrence of cardiac sarcoidosis, which was
histologically diagnosed at the time of autopsy. The remaining 3
patients who  had prior pulmonary-involvement of sarcoidosis did
not have recurrence or worsening of pulmonary/cardiac sarcoidosis
and their post-transplant course was uneventful.
Nine patients (64.3%) developed post-operative renal dysfunc-
tion with creatinine > 2.0 mg/dL. Length of hospitalization after HTx
also showed no signiﬁcant differences between the groups. Five
patients (35.7%) died after HTx at 9–1236 days (mean survival dura-
tion 41.0 ± 18.7 months). Two  patients died in the hospital (14.3%).
Causes of death were pneumonia, sepsis, recurrence of cardiac sar-
coidosis, primary graft failure, and malignancy as listed in Table 2.
The mean follow-up after transplant for all patients with sarcoido-
sis in this cohort was  55.1 ± 51.3 months.
Two patients, including those with pre-existing lung sarcoido-
sis, had been treated with maintenance steroid therapy prior to
HTx. Following HTx, all patients received triple immunosuppres-
sive regimen using calcineurin inhibitors, mycophenolate, and
steroids. Allograft cellular rejection occurred in 4 patients (28.5%)
at grade 3A. In 3 patients it occurred within 6 months after HTx
and in 1 patient 18 months post-HTx. The 4 patients were treated
with pulse steroid therapy and 2 of the 4 patients were also
treated with muromonab-CD3 therapy in addition to pulse steroid
therapy.
Two patients (14.3%) were diagnosed with recurrence of cardiac
sarcoidosis within 3 years after HTx. One patient died secondary
to ventricular ﬁbrillation after developing progressive cardiomy-
opathy because of sarcoidosis recurrence and rejection. A second
patient who also developed biopsy-conﬁrmed recurrence of cardiac
sarcoidosis did not show signs of rejection or cardiac failure and
it was  assumed that this recurrence had healed when subsequent
biopsies were negative for sarcoidosis (Table 2).
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Fig. 1. Kaplan–Meier survival curves of sarcoidosis patients and non-sarcoidosis
patients. Blue line indicates patients with sarcoidosis as a primary heart disease for
transplant and red line indicates patients with other heart disease. Pts, patients. (For
interpretation of the references to color in this ﬁgure legend, the reader is referred
to  the web version of the article.)
Kaplan–Meier analysis revealed that overall survival of sar-
coidosis patients tended to be lower than that of non-sarcoidosis
patients (Fig. 1). The overall survival rate of patients with sarcoido-
sis compared to non-sarcoidosis patients was  78.5% versus 87.2%
at 1 year and 58.9% versus 76.2% at 5 years (p = 0.09). The analy-
sis of survival showed that the 6 patients with known sarcoidosis
before HTx tended to have higher mortality post-HTx compared
to patients diagnosed at the time of HTx (1-year mortality: 87.5%
versus 66.7% and 5-year mortality: 72.9% versus 33.3%, p = 0.08,
Fig. 2) likely due to a more generalized disease process with additive
peripheral end-organ involvement and damage. Causes of death
were pneumonia, sepsis, recurrence of cardiac sarcoidosis, primary
graft failure, and malignancy.
Discussion
There has been debate as to whether HTx is an appropriate treat-
ment option for patients with cardiac sarcoidosis, because of the
possibility of recurrence of cardiac sarcoidosis in a transplanted
heart and involvement of other organs such as the lung which
could even occur after successful HTx. Further, a number of patients
develop multi-organ involvement although the death rate due to
Fig. 2. Kaplan–Meier survival curves of sarcoidosis patients, whose diagnosis was
made before and at the time of transplant, and non-sarcoidosis patients. Black line
indicates patients with other heart disease and gray line indicates patients with
sarcoidosis, of whom survival of patients with diagnosis of sarcoidosis was made
before transplant are shown in dashed-red line, and that of patients diagnosed at
the  time of transplant are shown in dotted-red line. Pts, patients; HTx, heart trans-
plantation. (For interpretation of the references to color in this ﬁgure legend, the
reader is referred to the web version of the article.)
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arcoidosis was reported to be less than 5% [7,8]. The largest pub-
ished experience of post-HTx outcome of patients with sarcoidosis
omes from a retrospective analysis of the UNOS database with
 total of 65 patients (mean age 46 years) with sarcoidosis who
nderwent HTx [3].  In contrast to our single center experience,
aidi et al. stated that one-year post-HTx survival was  better for
arcoidosis patients than for patients receiving transplantation for
ll other diagnoses (87.7% versus 84.5%, p = 0.03). The diagnosis of
ardiac sarcoidosis in their study based on the UNOS database was
he pre-transplant diagnostic code listed in the Heart Transplant
ecipient Registration Form of the UNOS; therefore, detailed pre-
ransplant clinical information and/or the histological evaluation
as not available. It is difﬁcult to differentiate cardiac sarcoido-
is from non-ischemic cardiomyopathy prior to the transplant. In
ur study, the diagnosis of sarcoidosis was based on histological
onﬁrmation at the time of transplant. We  speculate that this dis-
ordance of diagnostic criteria between the UNOS database and our
ohort may  contribute to the different results of post-transplant
rognosis between the studies. Indeed, our present observation
evealed that patients who  were diagnosed with sarcoidosis prior
o transplant showed worse survival than those with diagnosis after
ransplant, although it was not statistically signiﬁcant. We  specu-
ate that patients who received a diagnosis of sarcoidosis prior to
ransplant were more prone to be in a systemic pro-inﬂammatory
ondition, regardless of the presence or absence of clinically prob-
ematic co-morbidities related to sarcoidosis while on the waiting
ist. Pro-inﬂammatory state before transplant would persist after
ransplant, and may  contribute to a poor post-transplant outcome.
n addition, patients with known sarcoidosis were already treated
ith steroids before transplant and we tried not to completely
ean them off steroids after transplant, which may  also contribute
o their susceptibility to infection.
The clinical manifestations of cardiac sarcoidosis are largely
onspeciﬁc. As a result, diagnostic testing such as endomyocar-
ial biopsy or imaging may  be required, particularly in patients
ithout other manifestations of the disease [1,6,7,9,10].  A deﬁni-
ive histological diagnosis of cardiac sarcoidosis can be challenging
ecause the sarcoidosis granulomas can be missed by endocardial
iopsy and even serial biopsy might not always prove the diagnosis
11,12]. Endomyocardial biopsy has a low sensitivity approaching
0% in a series of 26 patients [12], which commonly leads to the
iagnosis of idiopathic dilated cardiomyopathy in those patients
10,13]. Some of our patients with sarcoidosis were successfully
ridged-to-transplant by LVAD, which has evolved into a promising
herapy for patients with advanced HF [14,15]. Histological evalua-
ion of LVAD core tissue would further help to diagnose the etiology
f HF. The deﬁnite diagnosis of cardiac sarcoidosis can often be
 surprising ﬁnding at the time of HTx on the explanted heart
11]. Diagnostic accuracy could be improved by additional tools
uch as magnetic resonance imaging with gadolinium enhance-
ent or radiocardiography including ﬂuorodeoxyglucose positron
mission tomography, which may  be helpful in the identiﬁca-
ion and follow-up of cardiac sarcoidosis but so far has not been
ully established [16]. In addition, recurrence of cardiac sarcoido-
is after transplant should be carefully observed, not only by the
se of endomyocardial biopsy but also using imaging modalities
ncluding serial echocardiograms to detect any change over the
ost-operative period compared to the ﬁndings immediately after
ransplant [17].
In this single-center, retrospective analysis of a small number
f cardiac sarcoidosis patients who underwent HTx, a concerning
[ology 60 (2012) 407–410
trend toward a higher mortality in patients with cardiac sarcoido-
sis was noted in the absence of signiﬁcant difference in end-organ
damage or other clinical risk factors. These results of our present
observation contrast with prior reports that have shown com-
parable or even better outcomes of this population compared to
non-sarcoidosis patients following HTx, although the diagnosis of
sarcoidosis in the previous study was made prior to transplant
at the time of listing and the diagnosis of our patients was con-
ﬁrmed according to the histological evaluation of explanted heart.
Our observations would argue for a careful candidate selection
in patients with known cardiac sarcoidosis. Further investiga-
tion would be required to evaluate an appropriate post-transplant
immunosuppressive regimen for patients with sarcoidosis, includ-
ing the continuation or withdrawal of steroid therapy in the chronic
phase.
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